Fig 1. Development of the prognostic model.
Kaplan—Meier curves for overall and progression-free survivals in the two groups (low risk and high risk) as defined by a prediction model based on the weighted expression of six genes (CCL2, CCR2, CXCL10, IL10RB, IL17B, and IL17R) (A, B). This Kaplan-Meier assessment of OS and PFS in patients with glioblastoma illustrates a risk score analysis using this signature in the TCGA cohort (C, D). The risk score has prognostic value of survival in the radiotherapy plus temozolomide group from both the CGGA and TCGA datasets (E, F, G, H).